17β-(N-heptylamino)-4-methyl-4-aza-5α-androstan-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17β-(N-heptylamino)-4-methyl-4-aza-5α-androstan-3-one
• 英文别名: (1S,3aS,3bS,5aR,9aR,9bS,11aS)-1-(heptylamino)-6,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinolin-7-one
• 化学式: C₂₆H₄₆N₂O
• 分子量: 402.664
• InChiKey: HBYMASUHZAEEHP-LOIFCEGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-二氯苯甲酰氯 、 17β-(N-heptylamino)-4-methyl-4-aza-5α-androstan-3-one 在 piperidinomethylpolystyrene resin 作用下， 以 四氢呋喃 为溶剂， 生成 N-[(1S,3aS,3bR,5aR,9aR,9bS,11aS)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinolin-1-yl]-2,6-dichloro-N-heptylbenzamide
  参考文献：
  名称：

  Potent and Selective Steroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 7, an Enzyme That Catalyzes the Reduction of the Key Hormones Estrone and Dihydrotestosterone

  摘要：

  17 beta-Hydroxysteroid dehydrogenase type 7 (17 beta-HSD7) catalyzes the reduction of estrone (E-1) into estradiol (E-2) and of dihydrotestosterone (DHT) into 5 alpha-androstane-3 beta,17 beta-diol (3 beta-diol), therefore modulating the level of mitogenic estrogens and androgens in humans. By classical and parallel chemistry, we generated several 4-methyl-4-aza-5 alpha-androstane derivatives differing in their C-17 substituent: 17 beta-formamide, 17 beta-benzamide, and 17 beta-tertiary amine. Best candidates in each category had demonstrated good inhibitory potency toward the conversion of E-1 into E-2 (IC50 = 189-451 nM) and also toward the conversion of DHT into 3 beta-diol (69-91% at 3 mu M). Inhibition assays with 17 beta-HSD1, 17 beta-HSD5, 5 alpha-reductase (5 alpha-R) 1 and 5 alpha-R2 revealed that 17 beta-HSD7 inhibitors with a 4-methyl-4-aza nucleus were also able to inhibit 5 alpha-Rs but not the other enzymes tested. Two 4-aza-5 alpha-androstane inhibitors were, however, selective and still showed good inhibition of 17 beta-HSD7. First selective and efficient inhibitors of 17 beta-HSD7 are now available for additional mechanistic and therapeutic studies.

  DOI：

  10.1021/jm900921c
• 作为产物：
  描述：

  在 盐酸 、 sodium cyanoborohydride 作用下， 以 甲醇 、 水 为溶剂， 以774 mg的产率得到17β-(N-heptylamino)-4-methyl-4-aza-5α-androstan-3-one
  参考文献：
  名称：

  Potent and Selective Steroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 7, an Enzyme That Catalyzes the Reduction of the Key Hormones Estrone and Dihydrotestosterone

  摘要：

  17 beta-Hydroxysteroid dehydrogenase type 7 (17 beta-HSD7) catalyzes the reduction of estrone (E-1) into estradiol (E-2) and of dihydrotestosterone (DHT) into 5 alpha-androstane-3 beta,17 beta-diol (3 beta-diol), therefore modulating the level of mitogenic estrogens and androgens in humans. By classical and parallel chemistry, we generated several 4-methyl-4-aza-5 alpha-androstane derivatives differing in their C-17 substituent: 17 beta-formamide, 17 beta-benzamide, and 17 beta-tertiary amine. Best candidates in each category had demonstrated good inhibitory potency toward the conversion of E-1 into E-2 (IC50 = 189-451 nM) and also toward the conversion of DHT into 3 beta-diol (69-91% at 3 mu M). Inhibition assays with 17 beta-HSD1, 17 beta-HSD5, 5 alpha-reductase (5 alpha-R) 1 and 5 alpha-R2 revealed that 17 beta-HSD7 inhibitors with a 4-methyl-4-aza nucleus were also able to inhibit 5 alpha-Rs but not the other enzymes tested. Two 4-aza-5 alpha-androstane inhibitors were, however, selective and still showed good inhibition of 17 beta-HSD7. First selective and efficient inhibitors of 17 beta-HSD7 are now available for additional mechanistic and therapeutic studies.

  DOI：

  10.1021/jm900921c

文献信息

• Synthesis and in Vitro Activity of 17.beta.-(N-Alkyl/arylformamido and N-alkyl/arylalkyl/arylamido)-4-methyl-4-aza-3-oxo-5.alpha.-androstan-3-ones as Inhibitors of Human 5.alpha.-Reductases and Antagonists of the Androgen Receptor
  作者：Xun Li、Shankar M. Singh、Fernand Labrie

  DOI：10.1021/jm00007a013

  日期：1995.3

  A number of 17 beta-(N-alkyl/arylformamido)- and 17 beta-[(N-alkyl/aryl)alkyl/arylamido]-3-oxo-4-aza- 5 alpha-steroids were prepared from 17 beta-hydroxy-4-azasteroids and evaluated as inhibitors of human 5 alpha-reductase and antagonists of the androgen receptor. Jones' oxidation of 17 beta-hydroxy compounds gave the 17-keto-4-azasteroids, which were treated with amines and NaBH(OAc)(3)/NaBH3CN to give 17 beta-(N-alkyl/arylamino)-4-azasteroids 10-27. Alternatively, the above-indicated compounds were prepared from amines and 17-keto-4-azasteroids to form imines, which were then reduced with NaBH4. Formylation of amines 10-27 gave 17 beta-(N-alkylformamides) 28-41; however, acylation afforded 17 beta-[(N-alkyl/aryl)alkyl/arylamides] 42-53. In comparison to N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxamide (4-MA; IC50 = 4.15 nM), 17 beta-(N-alkylformamido)-4-azasteroids were potent inhibitors of human type I 5 alpha-reductase, IC50 values of compounds 29, 30, 36, and 37 being measured as 3.05, 0.91, 2.19, and 2.35 nM, respectively. The structure-activity relationships suggest that the type I enzyme has preference for N-substituted straight alkyl side chains of four to five carbon atoms. On the other hand, formamides 32 (N-heptyl) and 33 (N-octyl), in addition to inhibiting the type I enzyme (IC(50)s = 9.57 and 16.9 nM, respectively), showed also strong inhibitory activity (IC50S = 14.0 and 18.4 nM, respectively) for human type II 5 alpha-reductase, in comparison to N-(1',1'dimethylethyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide (MK-906; IC50 = 4.53 nM) Other compounds in this series showed moderate activities (IC50 > 100 nM) on the type II enzyme. 17 beta-[(N-Alkyl/aryl)alkyl/arylamides] 45, 46, 48, and 51 exhibited highly potent inhibitory activity for human type I 5 alpha-reductase with IC(50)s of 1.77, 2.42, 2.93, and 5.44 nM, respectively, while moderate to no effect was observed on the type II enzyme (100 < IC50S < 1000 nM), except for compound 48 (IC50 = 3.75 nM). In another substitution pattern, N-aryl/alkylamides were studied; an electron-donating group increased the potency of compound 51, whereas an electron-withdrawing group decreased the potency of compounds 52 and 53 compared to parent compound 50. In addition to their 5 alpha-reductase activities, 17 beta-(N-alkylformamides) were also studied for their inhibitory activities on dihydrotestosterone (DHT)-stimulated proliferation of androgen-sensitive Shionogi mouse mammary carcinoma cells (clone SEM-107). The inhibition of DHT action on the proliferation of the androgen-sensitive cancer cells by formamido compounds showed moderate to good activity, IC50 values ranging from 45 to 100 nM as compared to hydroxyflutamide (IC50 = 52.5 nM).
• Potent and Selective Steroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 7, an Enzyme That Catalyzes the Reduction of the Key Hormones Estrone and Dihydrotestosterone
  作者：Édith Bellavance、Van Luu-The、Donald Poirier

  DOI：10.1021/jm900921c

  日期：2009.12.10

  17 beta-Hydroxysteroid dehydrogenase type 7 (17 beta-HSD7) catalyzes the reduction of estrone (E-1) into estradiol (E-2) and of dihydrotestosterone (DHT) into 5 alpha-androstane-3 beta,17 beta-diol (3 beta-diol), therefore modulating the level of mitogenic estrogens and androgens in humans. By classical and parallel chemistry, we generated several 4-methyl-4-aza-5 alpha-androstane derivatives differing in their C-17 substituent: 17 beta-formamide, 17 beta-benzamide, and 17 beta-tertiary amine. Best candidates in each category had demonstrated good inhibitory potency toward the conversion of E-1 into E-2 (IC50 = 189-451 nM) and also toward the conversion of DHT into 3 beta-diol (69-91% at 3 mu M). Inhibition assays with 17 beta-HSD1, 17 beta-HSD5, 5 alpha-reductase (5 alpha-R) 1 and 5 alpha-R2 revealed that 17 beta-HSD7 inhibitors with a 4-methyl-4-aza nucleus were also able to inhibit 5 alpha-Rs but not the other enzymes tested. Two 4-aza-5 alpha-androstane inhibitors were, however, selective and still showed good inhibition of 17 beta-HSD7. First selective and efficient inhibitors of 17 beta-HSD7 are now available for additional mechanistic and therapeutic studies.